ASCO 2025 — Let’s Talk About What’s Next in Oncology

Medelis will be attending ASCO 2025 in Chicago later this month. This year’s theme, Driving Knowledge to Action: Building a Better Future, really resonates with us — because that’s what we’re focused on every day: helping innovative oncology companies move from scientific insight to clinical impact.

If you’re heading to ASCO and working on advancing a new cancer therapy, we’d love to meet.

At Medelis, we work closely with startup to midsize biotech and pharma companies to support oncology trials from first-in-human through pivotal studies. We know what it takes to move fast, stay flexible, and still do things right — especially when every patient, and every milestone, matters.

Here’s how we can help your program succeed:

  • Early-phase trial expertise – We specialize in Phase I and II oncology studies, including complex designs and rare indications.
  • Hands-on senior team – Our leadership is directly involved in your trial, not just behind the scenes.
  • Thoughtful, efficient study design – We help you think strategically from the start to save time and resources later.
  • Strong site relationships – We work with investigators and sites who know oncology and are ready to enroll
  • Regulatory support you can trust – We guide INDs, FDA interactions, and compliance with confidence.

We believe smaller sponsors deserve a CRO partner that treats your trial like a top priority — because to us, it is.

Let’s Connect at ASCO

If you’re planning your trip to ASCO and want to talk about how to get your oncology program moving faster (and smarter), we’d love to grab a coffee or set up a quick meeting.

Let’s talk about where you’re headed — and how we can help you get there.

See you in Chicago.

Blog Categories